ClinicalTrials.gg

Celldex Therapeutics clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 51 studies whose lead sponsor is Celldex Therapeutics or one of 2 companies grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 12, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Celldex Therapeutics with Novartis and Hangzhou Highlightll Pharmaceutical →

Pipeline: 2 programs

Each counted once: 2 with a study Celldex Therapeutics leads registered in the last two years.

  • Phase 1
  • Phase 3

The 1 phase-3 program — sign in to see them, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Celldex Therapeutics’ own registered studies; Celldex Therapeutics’ own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Celldex Therapeutics’ studies test, most open studies first — 16 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 6 more

Coming up

1 of Celldex Therapeutics’ studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. D
  3. J’27
  4. F
  5. 1M
  6. A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

Add it to your calendar (.ics) → With an account.

All 51 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now36%Recruiting 2 · Enrolling by invitation 1
  • Under way, not recruiting48%
  • Completed3365%
  • Stopped early918%
  • Status unknown or other24%

Phase

  • Phase 127
  • Phase 222
  • Phase 35

Where

  • United States48
  • Germany13
  • Spain10
  • Poland9
  • Canada7
  • Italy6

Over the years

  1. 07
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 715
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 226

By the year each study started; 6 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Celldex Therapeutics.

  • Celldex Therapeutics
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    45 studies
  • CuraGen Corporation
    Acquired — became part of Celldex Therapeutics, Oct 1, 2009 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    4 studies →
  • Avant Immunotherapeutics
    Acquired — became part of Celldex Therapeutics, Mar 7, 2008 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    2 studies →

Studies

Recruiting first, then most recently updated. Showing 50 of 51. Browse all 51 →